Posted in

News And Events

Rate of hallucinations and hospitalizations in PD: which medication is the best?

Hallucinations and delusions from psychosis are not uncommon for people living with Parkinson’s disease (PD). According to the Parkinson’s Foundation, between 20-40% of people living with PD report hallucinations with the likelihood increasing as someone living with PD ages. The only FDA-approved medication for hallucinations in Parkinson disease is pimavanserin (commonly sold…

Differential contributions of depression, apathy, and anxiety to neuropsychological performance in Parkinson’s disease versus essential tremor

Congratulations Drs. Kelly Foote and Michael Okun on the publication of “Differential contributions of depression, apathy, and anxiety to neuropsychological performance in Parkinson’s disease versus essential tremor, ” which was published in the January 4th issue of the Journal of Clinical and Experimental Neuropsychology.   ABSTRACT Introduction Mood symptoms are…

Resident of the Month – January 2023

We are thrilled to announce our January Resident of the Month is Dr. Freddy Abraham. Dr. Abraham has been instrumental in the care of patients this past month, taking time to meet with patient’s families and coordinating care from a busy emergency department. He was especially helpful during his Night…

Comparison of Pimavanserin Versus Quetiapine for Hospitalization and Mortality Risk Among Medicare Beneficiaries with Parkinson’s Disease Psychosis

Congratulations to Drs. Melissa Armstrong and Michael Okun on the publication of “Comparison of Pimavanserin Versus Quetiapine for Hospitalization and Mortality Risk Among Medicare Beneficiaries with Parkinson’s Disease Psychosis,” which appears in the December 29th edition of Movement Disorders. ABSTRACT Background Pimavanserin is currently the only antipsychotic approved for Parkinson’s…

Turning Discovery in to Health – New NIH Grants in Neurology!

Congratulations to Dr. Diego E Rincon-Limas and Dr. Adamantios Mamais.  Dr Rincon-Limas has been awarded a new National Institutes of Health RO1 Grant titled “Harnessing new targets and mechanisms mediating AD pathogenesis.”   Dr. Mamais was also awarded a new National Institutes of Health R21 grant entitled, “Dysregulation of iron…

The Effects of Transcutaneous Vagus Nerve Stimulation on Functional Connectivity Within Semantic and Hippocampal Networks in Mild Cognitive Impairment

Congratulations Drs. Heilman and Dekosky on the publication of “The Effects of Transcutaneous Vagus Nerve Stimulation on Functional Connectivity Within Semantic and Hippocampal Networks in Mild Cognitive Impairment.” This article was published in the December 7th issue of Neurotherapeutics.     Abstract Better treatments are needed to improve cognition and…

The 10th Annual Stroke Conference

The 10th Annual Stroke Conference will focus on science, technology and practical applications in order to equip participants with the tools needed to deliver high quality, evidence-based, patient centered stroke care.  Topics Include: Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherosclerosis (CAPTIVA) Medical Management of…